QUALIGEN THERAPEUTICS INC. overview

Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China PR Newswire CARLSBAD, Calif., Jan. 26, 2021 CARLSBAD, Calif. , Jan. 26, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announces achievement of a milestone event which triggered a payment obligation from Yi Xin Zhen...

Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire CARLSBAD, Calif., Jan. 5, 2021 CARLSBAD, Calif. , Jan. 5, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that Michael Poirier , Chairman, Chief Executive Officer and President, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference to be...

Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook PR Newswire CARLSBAD, Calif., Dec. 22, 2020 CARLSBAD, Calif. , Dec. 22, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) , a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, announces that Michael Poirier , Chairman, Chief Executive Officer and President, has issued a letter to Qualigen's stockholders. The full text is as follows: To My...

Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering PR Newswire CARLSBAD, Calif., Dec. 18, 2020 CARLSBAD, Calif. , Dec. 18, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common stock, (ii) 1,000,000 pre-funded common stock Warrants (i.e., warrants to...

Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering PR Newswire CARLSBAD, Calif., Dec. 16, 2020 CARLSBAD, Calif. , Dec. 16, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 Common Shares, (ii) 1,000,000 Pre-Funded Warrants (iii) 1,348,314 Common Warrants exercisable...

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology PR Newswire CARLSBAD, Calif., Dec. 15, 2020 CARLSBAD, Calif. , Dec. 15, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a patent entitled "Anti-Nucleolin...

Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board - Amy Broidrick, a strategic and marketing executive with over 25 years of experience in biopharma companies - Sidney Emery, Jr., a senior executive with 50 years of leadership and business experience PR Newswire CARLSBAD, Calif., Dec. 8, 2020 CARLSBAD, Calif. , Dec. 8, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused...

Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials PR Newswire CARLSBAD, Calif., Dec. 2, 2020 CARLSBAD, Calif. , Dec. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that it has completed the recertification of its supply of AS1411, and has begun final formulation and filling for use in the Company's proposed Phase 2a efficacy trials of AS1411 for the treatment of patients with COVID-19. Qualigen plans...